Monocyte infiltration and activation of the coagulation system have been implicated in the pathophysiology of glomerulonephritis. In this study, spontaneous procoagulant activity (PCA) was measured in circulating mononuclear cells to determine whether elevated PCA correlated with the presence of proliferative glomerulonephritis in patients with systemic lupus erythematosus (SLE). No increase in PCA was found in 20 patients with end-stage renal failure, 8 patients with glomerulonephritis without SLE, and 10 patients undergoing abdominal surgical or orthopedic procedures as compared with 20 normal controls. In eight patients with SLE but with no apparent active renal disease, PCA was not elevated above normal basal levels. Seven additional patients with SLE who had only mesangial proliferation on biopsy also had no increase in PCA. In contrast, eight patients with focal or diffuse proliferative lupus nephritis, and one patient with membranous nephritis who ultimately developed a proliferative lesion, had a marked increase in PCA with >100 times the base-line levels. The activity was shown to originate in the monocyte fraction of the mononuclear cells and was shown to be capable of cleaving prothrombin directly. The prothrombinase activity was not Factor Xa, because it was not neutralized by anti-Factor X serum and was not inhibited by an established panel of Factor Xa inhibitors. Monocyte plasminogen activator determinations did not correlate with renal disease activity. We conclude that monocyte procoagulant activity, a direct prothrombinase, seems to correlate with endocapillary proliferation in lupus nephritis and could be a mediator of tissue injury.
Introduction
1. Abbreviations used in this paper: DFP, diisopropylfluorophosphate; GN, glomerulonephritis; LPS, lipopolysaccharide (endotoxin); PA, plasminogen activator; PAGE, polyacrylamide gel electrophoresis; PBM, purified blood mononuclear cells; PCA, procoagulant activity; PMSF, phenylmethylsulfonyl fluoride; PTT, partial thromboplastin time; SLE, systemic lupus erythematosus.
Clinical assessment, lupus serology, serum complement levels, serum immune complex levels, and renal function have shown good correlation with disease activity in several groups of patients with SLE (3-5) but are often not useful in the assessment of disease activity in individual patients suggesting other factors may be important in pathogenesis and activity.
A number of recent studies have demonstrated that macrophages are important mediators of injury in some forms of glomerulonephritis. Several studies suggest that proliferating cells within the glomerulus are derived from circulating monocytes as well as intrinsic glomerular cells (6, 7) . Holdsworth et al. (8) , in experimental glomerulonephritis in the rabbit, have shown that macrophages are present during the development of injury and that depletion with a specific anti-macrophage serum was able to abrogate glomerular injury. In a number of studies, the importance of the coagulation system in the pathogenesis of glomerulonephritis has been demonstrated.
In both human and animal models of crescentic glomerulonephritis, fibrin and platelets are present in Bowman's space; and in experimental models, the appearance of fibrin precedes the development of crescents (9) . Anticoagulation with heparin prevents injury in experimental nephritis and possibly in human disease (10, 11) . Defibrination with ancrod prevents the appearance of fibrin in the urinary space, and the development of crescents, and significantly lessens renal injury in nephrotoxic nephritis in rabbits (9) . Activation of the coagulation system and thrombosis have been noted in SLE, and recent data also suggest a therapeutic role for ancrod in patients with SLE and glomerulonephritis (12, 13) .
It has been known for a long time that lymphoid cells express procoagulant activity after stimulation both in vitro and in vivo (14) . The cellular source of this activity is the monocyte/macrophage, but T cells are necessary for the induction of these procoagulant monokines (15) . At least three procoagulant monokines have been defined in human mononuclear cells. First, the induction of thromboplastin (tissue factor) has been described in response to lipopolysaccharide (endotoxin; LPS) and lectins (concanavalin A and phytohemmaglutinin). Second, a Factor X activating factor produced by monocyte/macrophages has been demonstrated in response to tumors. Finally, a direct prothrombin activating factor (prothrombinase) that is unrelated to Factor Xa has been documented in response to specific lipoproteins and viral infection (16) .
In this report, we describe the spontaneous expression of monocyte procoagulant activity (PCA) by mononuclear cells, which directly correlated with endocapillary proliferation in patients with lupus nephritis.
Methods
Renal pathology. Renal biopsies were performed by the percutaneous or open wedge technique, and handled and processed in a standard manner. Specimens for histologic study were embedded in paraffin and sections were stained with hematoxylin and eosin, periodic acid-Schiff, and periodic acid-silver methionine. Tissue for immunofluorescence was snap frozen, sectioned, and stained with fluorescein isothiocyanate conjugated monospecific antisera against IgG, IgA, IgM, third component of human complement (C3), and fibrinogen (Cappel Laboratories, Cochranville, PA).
Tissue for electron microscopy was fixed in osmium tetroxide before mounting and viewing.
Pathologic diagnosis was made according to World Health Organization criteria (17) .
Cell isolation. Peripheral blood mononuclear cells were isolated from the heparinized peripheral blood of normal controls and patients by centrifugation over Ficoll-Hypaque at 1,400 g at 220C for 12 min. The cells were adjusted to 1 X 106/ml, and lymphocytes and monocytes were separated by adherence to fibronectin-coated plastic flat bottom 16-mm diam, 24-well plates (Flow Laboratories, McLean, VA) in 1-ml vol in complete medium (Dulbecco's modified essential medium containing 10% fetal calf serum, 25 Ag/ml aureomycin, grade II (Sigma Chemical Co., St. Louis, MO). After a 60-min incubation, the nonadherent cells were washed free from the plate. The adherent cells were recovered by incubation at 40C for 20 min with a solution containing 3 mM ethylene diaminetetraacetic acid. The recovery of cells was >84% and viability was >95% as demonstrated by trypan blue exclusion. Lymphocytes were defined by the failure of adherence, morphology, and failure of uptake of neutral red, and were <1% esterase positive. Monocytes were defiied by morphology, uptake of neutral red, and were >96% esterase positive as previously described (15 Assay of direct prothrombin cleavage. Factor X and prothrombin were isolated from Cohn fraction III as previously described (18 Laemmli (19) . Following electrophoresis, the gels were fixed, dried, and analyzed by autoradiography for 1251_ prothrombin and its cleavage products. Assessment of susceptibility of PCA from patients with SLE to protease inhibitors was performed as described previously (18) . Cell homogenates (50 Mi) were incubated with antithrombin III (10 Ml/ml) in the presence or absence of heparin (I U/ml), trasylol (10 U/ml), soybean trypsin inhibitor (10 Ml/ml), benzamidine (I mM), phenylmethylsulfonyl fluoride (PMSF; 1 mM), or diisopropylfluorophosphate (DFP; 2.5 and 10 mM). After a 5-min incubation with inhibitor at 220C, 10 Ml of '25I-prothrombin and 10 Al of 25 mM CaC12 were added and the reaction mixture incubated an additional 30 min at 370C. 251-prothrombin cleavage was then assessed by SDS-polyacrylamide gel electrophoresis (PAGE) and autoradiography. Human Factor Xa (0.5 Mg/ml) in the presence of homogenates of unstimulated control cells was treated identically for comparison.
Antibody neutralization of PCA was examined using rabbit antisera to human Factor X as previously described (18) . Human Factor Xa in the presence of control homogenates of 106 PBM or homogenates from patients with SLE and other renal diseases was added to rabbit anti-Factor X immune serum. Aliquots were removed, and after a 6-h incubation at 220C, were combined with 1251I-prothrombin and CaCI2 at 370C for 30 min and analyzed following SDS-PAGE and autoradiography.
Plasminogen activator. Plasminogen was isolated from citrated normal human fresh frozen plasma according to a modification of the method of Deutsch and Mertz (20) . 70 IU ancrod (Connaught Laboratories, Ltd., Willowdale, Ontario, Canada) was added to each liter of plasma and the plasma was stirred gently overnight at 40C. After filtration, the plasma was diluted 1:1 with 0.1 M P04, pH 7.4, containing 3 mM EDTA and 2 mM PMSF. The solution was loaded onto a Sepharose-Lysine column, the column washed with P04 buffer pH 7.4 containing 3 mM EDTA and 2 mM PMSF until the optical density at 280 nM was <0.01, and the plasminogen was then eluted off of the column with 0.2 M epsilon amino caproic acid in 0.3 M P04 containing 3 mM EDTA and 2 mM PMSF. The plasminogen was then dialyzed overnight in 5 mM P04 buffer, pH 7.4, containing 2 mM PMSF with frequent changes. The plasminogen was then Iyophilized and resuspended in 5 mM P04 buffer, pH 7.4, and passed through a Sephadex column. The protein peak was recovered and dialyzed against 0.1 M Tris buffered saline at 4°C. Protein concentration was determined in a standard Lowry assay, and plasminogen was stored in aliquots at -70°C until use.
Fibrinogen (Kabi; Sigma Chemical Co., St. Louis, MO) was radioiodinated enzymatically with immobilized lactoperoxidase and glucose oxidase and diluted with cold fibrinogen. Plastic flat-bottom 16-mM diam 24-well plates (Linbro Plastics, McLean, VA) were then coated with the fibrinogen and dried at room temperature for 3 d. Fibrinogen was then converted to fibrin by adding acid treated fetal calf serum as a source of thrombin to each well for 4 h at 37°C. To each well, 1 ml of 0.1% gelatin in Tris buffered saline was added, which contained 10 Mg of plasminogen and an aliquot of cellular homogenate from control patients, patients with SLE, streptokinase (Sigma Chemical Co., St. Louis, MO), or plasmin as positive controls. After a 45-min incubation at 370C, the supernatants were removed and counted in a gamma counter. Results are expressed as the mean of triplicate samples of percent of maximum 125I released per 106 monocytes as compared with cpm released by the plasmin control.
Results
Patient profiles. 24 patients with SLE were studied through the Rheumatic Disease Unit of the Wellesley Hospital. All patients met at least four American Rheumatism Association criteria for the diagnosis of SLE. Patients were evaluated for organ systems involved, serology, serum complement levels, and therapy at the time of the study (Table I ). All patients were seropositive (Table I) at the time of diagnosis, and 18 remained positive at the time of the study. 11 of the patients had normal serum complement levels. 20 patients had skin lesions, 15 had arthritis, 6 had Raynaud's phenomenon, 3 had serositis, 9 had central nervous system involvement, and 5 had frank vasculitis. 15 of the patients were receiving prednisone, 2 patients were receiving azothiaprine (imuran), and the remainder received salicylates, chloroquine, or nonsteroidal antiinflammatory agents. 3 patients were on no therapy at the time of the study (Table I) . Coagulation parameters were studied in all patients before entry into the study. These included partial thromboplastin time (PTT), prothrombin time, and platelet count. PTT was within normal limits in all patients except for patient 10, in which the PTT was below normal values. The prothrombin time was normal in all patients except for patient 21 , who was on coumadin at the time of the study because of previous consumptive coagulopathy. Four patients had mild thrombocytopenia (Table II) . No thrombotic episodes were seen in any patient at the time of this study except for patient 14, who had renal vein thrombosis and who was treated with coumadin after completion of the study.
Spontaneous expression ofPCA. The surface expression of PCA by suspensions of viable PBM as well as the total content PCA contained in lysed cell suspensions was determined. Since renal failure was likely to coexist in some patients with lupus nephritis, the effect of renal failure on PCA was studied in 20 patients with stable end-stage renal failure who were receiving regular dialysis, and this was compared with 20 normal controls. Of the patients with end-stage renal failure, 12 were on hemodialysis and 8 were on peritoneal dialysis. Since surgery has been reported to be associated with a hypercoagulable state, 10 patients were studied before and after abdominal or orthopedic procedures. Additionally, eight patients with heavy proteinuria and glomerulonephritis without SLE were studied.
Five of these patients had minimal lesion glomerulonephritis, one had idiopathic membranous glomerulonephritis, and two had idiopathic mesangial proliferative glomerulonephritis. Both viable and total content PCA were equivalent in all of these patient groups (Table III) . Viable PCA was 25% of total content PCA. Monocytes were the cellular source of >92% of both the viable and total content PCA as determined by assaying purified cell populations (data not shown).
Monocyte PCA, renal function, and pathology in patients with SLE. In the 24 patients with SLE studied, microscopic urinalysis, creatinine clearance, 24-h urinary protein, and concurrent renal biopsy where available were compared with monocyte/macrophage total content PCA. Clinical and laboratory assessments were performed independently and each group of investigators was not aware of the results of the other until after the study had been completed. The patients were divided into three groups on the basis (Table VIII) . Furthermore, both viable cells as well inhibitor, trasylol, benzamidine, PMSF, or specific antibody as cellular homogenates from monocytes from these patients, to Factor X, whereas >75% inhibition of Factor Xa was when added to isolated prothrombin and fibrinogen in the observed in the presence of these protease inhibitors. Furtherpresence of CaCl2, initiated the formation of a fibrin clot. In more, whereas 10 mM DFP was required to inhibit Factor Xa contrast, when PBM from controls or patients in Group 1 and cleavage by prothrombin, as little as 2.0 mM DFP inhibited 3 were added to prothrombin and fibrinogen, no clot formation the cellular prothrombinase (data not shown). was observed.
Monocyte plasminogen activator levels in patients with To further demonstrate that this augmented spontaneous SLE. Plasminogen activator (PA), a neutral protease, is a PCA had direct prothrombinase activity, cellular homogenates monocyte product associated with monocyte activation. Ad- ditionally, its action (fibrinolysis) is the opposite of the monocyte PCA. Cells from most of the patients in the study had monocyte PA determinations, and as can be seen, the PA showed no correlation with activity of SLE or PCA (Tables  IV, V , and VII). In a few cases, however (patients 1, 7, and 22), an inverse relationship existed between monocyte PCA and PA suggesting that the production of these two proteases might be linked although in two other patients (patient 14 and 15) both monocyte PCA and PA were elevated.
Discussion
Renal involvement in SLE is one of the most significant factors in determining morbidity and mortality (2) . Reports by Baldwin et al. (1) suggest that the renal pathology in patients with SLE correlates well with the prognosis. While investigators disagree concerning whether there is a prognostic advantage to the data provided by renal biopsy as compared with conventional laboratory assessment of renal function (21, 22) , some authors have described significant numbers of patients with normal renal laboratory variables who had diffuse proliferative glomerulonephritis on renal biopsy (23, 24) . The results of this study demonstrate that the spontaneous expression of monocyte/macrophage PCA correlated with endocapillary proliferation in patients with glomerulonephritis and SLE. Furthermore, this correlation was superior to that observed with either lupus serology, serum complement levels, or laboratory indices of renal function. In the 24 patients studied with SLE, rno correlation was observed between the extrarenal manifestations of SLE and monocyte PCA. Admittedly, since current renal pathology was not available in group 3, one cannot draw firm conclusions in these patients. However, a striking correlation was observed between evidence of endocapillary proliferation, active renal lesions, and expression of PCA in the other patients. It is noteworthy that patient 15, who had no laboratory evidence of renal disease, and patients 10 and 11, who had only minimal laboratory abnormalities, had diffuse proliferative glomerulonephritis with active lesions on biopsy and marked elevations in monocyte PCA. Similarly, patient 7, who presented with apparent acute onset of renal failure and an active urine sediment, and who was felt to have diffuse proliferative glomerulonephritis clinically, was found on biopsy to have a mesangial lesion with interstitial fibrosis and no elevation in monocyte PCA. In patient 16, a marked elevation in monocyte PCA was found, although renal biopsy only demonstrated a membranous lesion. The significance of this is unclear. This may represent a false positive, or the expression of PCA may have antedated the subsequent development of the diffuse proliferative lesion that was seen in this patient. In four of the patients who initially had marked elevations of monocyte PCA, a fall in PCA occurred with successful treatment, although repeat renal biopsy was not performed.
Activation of the coagulation system in SLE has been previously reported by a number of investigators. Kant et al. (25) reported on the high incidence of glomerular thrombi in biopsies from patients with SLE. They also suggested that the presence of fibrin without the third component of human complement in patients with circulating anticoagulants was evidence in favor of cell-mediated reactions as opposed to immune complex mediated disease. Hardin et al. (26) found elevated fibrinopeptide A levels in all patients with active SLE, and the increase occurred in proportion to the degree of activity of disease.
Cells of the monocyte/macrophage series play a central role in the immune and inflammatory response to a variety of agents (15, (27) (28) (29) . The responses can result from either the direct interaction of the agents with the monocyte/macrophages or through the interactions of these cells with T and B lymphocytes and their products (15) . Monocytes and macro- Monocyte PCA could be an important mediator in disease activity by a number of mechanisms. It is conceivable that the induction of PCA could play a role in disease by direct activation of the coagulation system, which could result in regional microcirculatory disturbances in conjunction with fibrin formation. However, the failure to find thrombi and/or fibrin in all of the patients we have studied who expressed augmented PCA might mitigate against this possibility. Admittedly, detection of fibrin by immunofluorescent techniques is insensitive. However, studies of Kant and co-workers (25) , who looked very carefully for glomerular thrombi, were able to show thrombi in only 50% of patients with SLE and proliferative glomerulonephritis (GN). Thus, our findings agree with other published data. Second, since it has recently been shown that thrombin is a potent chemoattractant for human monocytes, the production of prothrombinase may play a role in the development of the cellular infiltrate that occurs in the kidneys of patients with active disease, and thus contribute to the immunologic injury (39). It has been shown that the expression of monocyte PCA correlates directly with the delayed cutaneous hypersensitivity reaction, and thus, the prothrombinase may be a mechanism by which monocytes recruit appropriate effector cells after contact with foreign antigens. Additionally, as PCA is a serine protease, it could alter receptors on the surface of target cells, making them more susceptible to attack by other cellular systems. The fact that monocyte PA did not correlate with renal activity in this study strengthens the importance of PCA as a mediator in GN and further defines this molecule as a unique activity and not just a signal of macrophage activation.
